tysabri

Novartis AG (NVS) announced Wednesday that a two-year Phase III study involving more than 4,000 patients worldwide shows that a new drug significantly reduces relapses and disability progression of multiple sclerosis. The chronic, irreversible disease attacks the central nervous system and is...